S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
OTCMKTS:SGIOY

Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis

$12.79
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$12.77
$12.81
50-Day Range
$11.66
$13.44
52-Week Range
$10.10
$13.67
Volume
37,575 shs
Average Volume
28,810 shs
Market Capitalization
$15.73 billion
P/E Ratio
13.61
Dividend Yield
1.33%
Price Target
N/A

Shionogi & Co., Ltd. MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-11.83%
From $0.93 to $0.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.52 out of 5 stars

SGIOY stock logo

About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOY)

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

SGIOY Stock Price History

SGIOY Stock News Headlines

SGIOY Shionogi & Co., Ltd.
Shionogi & Co. Ltd. ADR
my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
Shionogi & Co., Ltd. (4507)
Here's what to expect from Shionogi's earnings
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Shionogi & Co., Ltd. (SGIOF)
Shionogi seeks Japan approval for COVID-19 vaccine
Japan Approves First Homegrown Covid-19 Antiviral Pill
Shionogi & Co., Ltd. (SGIOY)
See More Headlines
Receive SGIOY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:SGIOY
Fax
N/A
Employees
5,680
Year Founded
N/A

Profitability

Net Income
$1.37 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.23 billion
Cash Flow
$1.24 per share
Book Value
$6.75 per share

Miscellaneous

Outstanding Shares
1,229,550,000
Free Float
N/A
Market Cap
$15.73 billion
Optionable
Not Optionable
Beta
0.21
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Isao Teshirogi Ph.D. (Age 65)
    CEO, President & Representative Director
    Comp: $1.97M
  • Susumu Mitsumori
    Vice President of Finance & Accounting Department
  • Mr. Kazuhiro Hatanaka
    Senior Executive Officer & Senior VP of Administration Division
  • Mr. Takeshi Shiota Ph.D.
    Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
  • Mr. Yoshimasa Kyokawa
    Vice President of Corporate Communications & Secretary Office
  • Yoshihiro Furuya
    Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
  • Mr. Kohji Hanasaki Ph.D.
    Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division
  • Dr. John A. Keller Ph.D. (Age 59)
    Senior Executive Officer and Senior VP of R&D Supervisory Unit
  • Akira Kato Ph.D.
    Corporate Officer & President of Shionogi Pharma Co., Ltd
  • Dr. Ryuichi Kiyama Ph.D.
    Senior Executive Officer & Senior VP of Corporate Strategy Division

SGIOY Stock Analysis - Frequently Asked Questions

Should I buy or sell Shionogi & Co., Ltd. stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shionogi & Co., Ltd. in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" SGIOY shares.
View SGIOY analyst ratings
or view top-rated stocks.

How have SGIOY shares performed in 2024?

Shionogi & Co., Ltd.'s stock was trading at $11.9720 at the beginning of the year. Since then, SGIOY stock has increased by 6.8% and is now trading at $12.79.
View the best growth stocks for 2024 here
.

Are investors shorting Shionogi & Co., Ltd.?

Shionogi & Co., Ltd. saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 12,100 shares, an increase of 236.1% from the February 14th total of 3,600 shares. Based on an average daily trading volume, of 107,500 shares, the days-to-cover ratio is presently 0.1 days.
View Shionogi & Co., Ltd.'s Short Interest
.

How were Shionogi & Co., Ltd.'s earnings last quarter?

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) issued its quarterly earnings results on Wednesday, January, 31st. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.33 by $0.11. The firm had revenue of $719.72 million for the quarter. Shionogi & Co., Ltd. had a net margin of 36.27% and a trailing twelve-month return on equity of 12.90%.

Is Shionogi & Co., Ltd. a good dividend stock?

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) pays an annual dividend of $0.17 per share and currently has a dividend yield of 1.35%. The dividend payout ratio is 18.09%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SGIOY will have a dividend payout ratio of 20.73% next year. This indicates that the company will be able to sustain or increase its dividend.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SGIOY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners